Brain Ischemia - Pipeline Review, H1 2017

  • ID: 4267354
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CohBar Inc
  • NeuroNascent Inc
  • NeurOp Inc
  • NoNO Inc
  • Vect-Horus SAS
  • MORE
Brain Ischemia - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides an overview of the Brain Ischemia (Central Nervous System) pipeline landscape.

Brain ischemia is a stroke is when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of stroke is atherosclerosis. Symptoms include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. Treatment includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Ischemia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Brain Ischemia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Ischemia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Brain Ischemia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Brain Ischemia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Brain Ischemia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Brain Ischemia (Central Nervous System)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Brain Ischemia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Brain Ischemia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CohBar Inc
  • NeuroNascent Inc
  • NeurOp Inc
  • NoNO Inc
  • Vect-Horus SAS
  • MORE
Introduction

Brain Ischemia - Overview

Brain Ischemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Brain Ischemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Brain Ischemia - Companies Involved in Therapeutics Development

CohBar Inc

Lixte Biotechnology Holdings Inc

NeuroNascent Inc

NeurOp Inc

NoNO Inc

Prolong Pharmaceuticals LLC

Spectrum Pharmaceuticals Inc

Vect-Horus SAS

Brain Ischemia - Drug Profiles

2-CCPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADA-409 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIDEM-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIGB-845 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit SRC-ND2 Interaction for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAU-0901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-10679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phycocyanobilin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPI-1620 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VHN-439 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Brain Ischemia - Dormant Projects

Brain Ischemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Brain Ischemia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Brain Ischemia - Pipeline by CohBar Inc, H1

Brain Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1

Brain Ischemia - Pipeline by NeuroNascent Inc, H1

Brain Ischemia - Pipeline by NeurOp Inc, H1

Brain Ischemia - Pipeline by NoNO Inc, H1

Brain Ischemia - Pipeline by Prolong Pharmaceuticals LLC, H1

Brain Ischemia - Pipeline by Spectrum Pharmaceuticals Inc, H1

Brain Ischemia - Pipeline by Vect-Horus SAS, H1

Brain Ischemia - Dormant Projects, H1

Brain Ischemia - Discontinued Products, H1

List of Figures:

Number of Products under Development for Brain Ischemia, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CohBar Inc
  • Lixte Biotechnology Holdings Inc
  • NeuroNascent Inc
  • NeurOp Inc
  • NoNO Inc
  • Prolong Pharmaceuticals LLC
  • Spectrum Pharmaceuticals Inc
  • Vect-Horus SAS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll